Affinage

LRP1B

Low-density lipoprotein receptor-related protein 1B · UniProt Q9NZR2

Length
4599 aa
Mass
515.5 kDa
Annotated
2026-06-10
67 papers in source corpus 22 papers cited in narrative 22 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/8 claims corpus-supported (88%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

LRP1B is a ~600 kDa single-chain endocytic receptor of the LDL receptor family that internalizes and degrades multiple ligands shared with LRP1 — including the receptor-associated protein, urokinase- and tissue-type plasminogen activators, and PAI-1 — but with markedly slower internalization kinetics (PMID:11384978). Unlike LRP1, the protein is not furin-cleaved and exists as a single polypeptide whose released soluble ectodomain is itself sufficient for embryonic viability in mice, consistent with a function as an extracellular scavenger of signaling ligands (PMID:15082773, PMID:20383322). Its ectodomains directly bind fibrinogen and apoE-carrying lipoproteins and mediate VLDL internalization (PMID:21420681). The cytoplasmic tail is phosphorylated by PKCα ~100-fold more efficiently than that of LRP1, and this phosphorylation is blocked by PICK1 binding to the receptor C-terminus (PMID:19071120). Through receptor-mediated catabolism of cell-surface partners, LRP1B restrains cell migration: in smooth muscle cells it binds and internalizes uPAR, lowering uPAR and PDGFRβ levels and dampening ERK1/2 signaling and migration (PMID:15166012, PMID:15882972). Across diverse cancers LRP1B acts as a growth and invasion suppressor whose promoter is silenced by CpG hypermethylation; restoration of expression impairs colony formation, proliferation, invasion, and tumor growth (PMID:15172977, PMID:27626682, PMID:21057533). Mechanistically it suppresses Wnt/β-catenin signaling by binding DVL2 and blocking the DVL2–Axin interaction (PMID:28408316), binds NCSTN to modulate PI3K/AKT signaling and lipid metabolism (PMID:37492741, PMID:33324588), and controls STAT3 phosphorylation and SLC7A11 to govern ferroptosis sensitivity (PMID:39660409). LRP1B expression is also required for C1q-mediated neuroprotection against amyloid-β toxicity (PMID:23150673).

Mechanistic history

Synthesis pass · year-by-year structured walk · 14 steps
  1. 2001 High

    Established that LRP1B is a functional endocytic receptor sharing LRP1 ligands, answering whether this homolog actually internalizes cargo and how it compares kinetically.

    Evidence Domain IV minireceptor (mLRP1B4) stable cell lines with ligand binding, internalization, and degradation assays

    PMID:11384978

    Open questions at the time
    • Tested a minireceptor rather than full-length protein
    • Slow internalization kinetics mechanistically unexplained
    • Physiological ligand repertoire not exhausted
  2. 2004 Medium

    Defined the receptor's molecular architecture as an uncleaved single polypeptide and identified the first cytoplasmic-tail interactors, framing how the intracellular domain might signal.

    Evidence Immunoblotting of knockout/knockin mouse tissues and yeast two-hybrid with the intracellular domain (PSD-95, AIP)

    PMID:15082773

    Open questions at the time
    • Functional consequences of PSD-95/AIP binding not established
    • No structural mapping of binding sites
  3. 2004 Medium

    Showed LRP1B is a tumor suppressor silenced epigenetically, explaining why it is recurrently lost in carcinomas without deletion.

    Evidence Array CGH, bisulfite sequencing, 5-aza demethylation rescue, and colony formation after LRP1B restoration in esophageal carcinoma cells

    PMID:15172977

    Open questions at the time
    • Mechanism by which restored LRP1B suppresses growth not defined
    • Single tumor type
  4. 2005 High

    Linked LRP1B to control of smooth muscle migration through catabolism of uPAR and PDGFRβ, providing a concrete receptor-clearance mechanism.

    Evidence Co-IP, metabolic labeling, anti-LRP1B functional antibody, and migration/invasion assays in cultured and plaque-derived SMCs

    PMID:15166012 PMID:15882972

    Open questions at the time
    • Whether clearance is via degradation vs. trafficking partially resolved
    • In vivo vascular phenotype not tested with genetic models
  5. 2008 High

    Identified PICK1 as a regulator of LRP1B phosphorylation and revealed the cytoplasmic tail is a far better PKCα substrate than LRP1, distinguishing the two receptors functionally.

    Evidence Yeast two-hybrid, reciprocal co-IP, and in vitro PKCα kinase assays

    PMID:19071120

    Open questions at the time
    • Downstream effect of tail phosphorylation on trafficking unknown
    • PICK1 regulation not tested in vivo
  6. 2010 Medium

    Demonstrated genetically that the soluble ectodomain alone supports viability, establishing an extracellular scavenger function independent of the membrane-anchored receptor.

    Evidence Mouse truncation alleles releasing the ECD versus null alleles, with embryonic lethality phenotyping and blastocyst culture

    PMID:20383322

    Open questions at the time
    • Specific scavenged ligands responsible for viability not identified
    • Relative contribution of membrane vs. soluble forms unresolved
  7. 2011 High

    Expanded the ligand repertoire to fibrinogen and apoE-lipoproteins/VLDL, connecting LRP1B to lipid and hemostatic ligand clearance.

    Evidence Affinity chromatography/MS, co-IP, lipoprotein binding, and VLDL internalization with minireceptor cells

    PMID:21420681

    Open questions at the time
    • Physiological significance of lipoprotein uptake in vivo not shown
    • Affinity relative to LRP1 not quantified
  8. 2012 Medium

    Revealed a neuroprotective role requiring LRP1B downstream of C1q against amyloid-β toxicity, extending function beyond cancer/vascular contexts.

    Evidence siRNA silencing in primary neurons with Aβ neurotoxicity assays and hippocampal expression in C1q-deficient AD mice

    PMID:23150673

    Open questions at the time
    • Molecular mechanism of LRP1B-mediated protection undefined
    • Whether LRP1B binds C1q directly not established
  9. 2012 Medium

    Showed LRP1B functions as an endocytic receptor for liposomal drug delivery, with direct therapeutic relevance for drug sensitivity.

    Evidence Bidirectional knockdown/overexpression in ovarian cancer lines with liposomal vs. free doxorubicin cytotoxicity assays

    PMID:22896685

    Open questions at the time
    • Liposome recognition determinants not defined
    • Single tumor type
  10. 2013 Medium

    Connected LRP1B loss to cytoskeletal and adhesion remodeling via RhoA/Cdc42, providing a mechanism for the migratory/invasive phenotype.

    Evidence shRNA knockdown with anchorage-independent growth, migration/invasion assays, focal adhesion Western blots, and Cdc42/RhoA activity assays

    PMID:23521319

    Open questions at the time
    • How surface receptor loss feeds into GTPase activation unknown
    • No rescue experiment reported
  11. 2017 Medium

    Defined a molecular mechanism for Wnt suppression: LRP1B binds DVL2 and blocks DVL2–Axin, linking the receptor to a canonical oncogenic pathway.

    Evidence Co-IP, competitive co-IP, TCF reporter assays, and growth/metastasis assays in colon cancer cells

    PMID:28408316

    Open questions at the time
    • Whether the interaction is direct and which domain mediates it unclear
    • Subcellular site of DVL2 engagement not mapped
  12. 2022 Medium

    Established LRP1B as a tumor suppressor across multiple cancers acting through NCSTN/PI3K-AKT, lipid metabolism/AMPK, and ER stress, with loss conferring therapy resistance.

    Evidence Co-IP, CRISPR knockdown/activation, pathway Westerns, lipid imaging, and in vitro/in vivo drug- and radiation-resistance assays across HCC, OPSCC, and glioblastoma models

    PMID:33324588 PMID:35389768 PMID:37492741 PMID:37511044 PMID:37778229

    Open questions at the time
    • Convergence of these multiple downstream pathways onto one mechanism not unified
    • ER stress link rests on expression changes without direct mechanistic demonstration
  13. 2024 Medium

    Showed LRP1B governs ferroptosis sensitivity and immunotherapy response via STAT3-driven SLC7A11 control, linking the receptor to redox/immune vulnerability.

    Evidence ChIP, dual-luciferase reporter, ferroptosis flow cytometry, and in vivo anti-PD-1 experiments in NSCLC

    PMID:39660409

    Open questions at the time
    • How a surface receptor controls STAT3 phosphorylation not mechanistically defined
    • IL-6-JAK-STAT3 secretory link to ferroptosis only partially connected
  14. 2025 Medium

    Identified DNMT3B as a direct epigenetic silencer of LRP1B, closing the loop on how the tumor suppressor is inactivated.

    Evidence ChIP, luciferase reporter, shRNA, rescue/epistasis, and in vivo transplantation in pheochromocytoma

    PMID:40346661

    Open questions at the time
    • Upstream signals driving DNMT3B recruitment unknown
    • Generality across other tumor types not tested

Open questions

Synthesis pass · forward-looking unresolved questions
  • It remains unresolved how the single endocytic/scavenging activity of LRP1B mechanistically gives rise to its many reported downstream signaling outputs (Wnt, PI3K/AKT, STAT3, AMPK, RhoA), and whether these reflect a common cargo-clearance mechanism.
  • No unifying biochemical model linking receptor endocytosis to the diverse pathway effects
  • Structural basis of ligand and partner selectivity undetermined
  • In vivo physiological function of full-length receptor largely uncharacterized

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0038024 cargo receptor activity 3 GO:0098772 molecular function regulator activity 3 GO:0140313 molecular sequestering activity 2
Localization
GO:0005576 extracellular region 3 GO:0005886 plasma membrane 3
Pathway
R-HSA-162582 Signal Transduction 4 R-HSA-1643685 Disease 4 R-HSA-5653656 Vesicle-mediated transport 3 R-HSA-1430728 Metabolism 1
Partners
DVL2FIBRINOGENNCSTNPDGFRBPICK1PKCALPHAPSD-95UPAR

Evidence

Reading pass · 22 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2001 LRP1B (mLRP1B4 minireceptor) binds, internalizes, and mediates degradation of multiple LRP1 ligands including receptor-associated protein, urokinase plasminogen activator, tissue-type plasminogen activator, and plasminogen activator inhibitor type-1, but with markedly diminished internalization kinetics compared to LRP1. Stable cell line expression of domain IV minireceptor (mLRP1B4); ligand binding, internalization, and degradation assays The Journal of biological chemistry High 11384978
2004 LRP1B protein exists as a single ~600 kDa polypeptide (unlike LRP1 which is cleaved by furin), and the intracellular domain binds two proteins identified by yeast two-hybrid: PSD-95 (postsynaptic density protein 95) and AIP (aryl hydrocarbon receptor-interacting protein). Immunoblotting of LRP1b knockout/knockin mouse tissues; yeast two-hybrid screen with LRP1b intracellular domain as bait Molecular and cellular biology Medium 15082773
2004 LRP1B attenuates smooth muscle cell migration by binding and internalizing urokinase-type plasminogen activator receptor (uPAR), thereby reducing membrane levels of uPAR and PDGFRβ; functional inhibition of LRP1B with anti-LRP1B IgY increased PDGFRβ protein levels, ERK1/2 phosphorylation, and SMC migration/invasion. Cell surface assays, internalization assays, co-immunoprecipitation, metabolic labeling, anti-LRP1B antibody functional inhibition, migration/invasion assays in cultured SMCs Arteriosclerosis, thrombosis, and vascular biology High 15166012
2005 LRP1B expression is negatively correlated with PDGFRβ levels in intimal smooth muscle cells from atherosclerotic plaques; functional inhibition of LRP1B increases PDGFRβ-mediated ERK1/2 phosphorylation and SMC migration, confirming LRP1B regulates SMC migration through PDGFRβ catabolism. Isolation and culture of SMC subpopulations from rabbit aortic plaques; anti-LRP1B IgY functional inhibition; Western blot; migration/invasion assays Biochemical and biophysical research communications Medium 15882972
2008 Six intracellular binding partners of LRP1B were identified by yeast two-hybrid and confirmed by co-immunoprecipitation. PICK1 binds the C-terminus of LRP1B; the LRP1B cytoplasmic domain is phosphorylated by PKCα ~100-fold more efficiently than LRP1; PICK1 binding inhibits PKCα-mediated phosphorylation of LRP1B but not LRP1. Yeast two-hybrid screen; co-immunoprecipitation; in vitro kinase assay with PKCα FEBS letters High 19071120
2010 The soluble extracellular domain of LRP1B, when released into the extracellular space, is sufficient to support embryonic viability in mice (truncation alleles releasing the ECD are viable whereas null mutations cause early embryonic lethality), suggesting the LRP1B ECD functions as a scavenger for signaling ligands in the extracellular space. Gene targeting in mice creating transmembrane/intracellular domain truncation alleles vs. null alleles; embryonic lethality phenotyping; blastocyst culture PloS one Medium 20383322
2010 LRP1B inactivation in thyroid cancer cells leads to reduced matrix metalloproteinase 2 (MMP2) in the extracellular medium and decreased invasion; restoration of LRP1B expression impairs tumor growth in vitro and in vivo and inhibits cell invasion, placing LRP1B as a modulator of the extracellular environment. CpG island reporter methylation assays; miRNA target validation; LRP1B restoration (transfection); in vitro invasion assay; in vivo tumor growth assay; MMP2 measurement in conditioned medium Oncogene Medium 21057533
2011 LRP1B ectodomains directly bind fibrinogen (confirmed by co-immunoprecipitation) and apoE-carrying lipoproteins (lipoprotein binding assay); cells expressing an LRP1B minireceptor bind and internalize VLDL. Affinity chromatography from human plasma with FLAG-tagged LRP1B ectodomains; mass spectrometry; co-immunoprecipitation; lipoprotein binding assay; internalization assay with LRP1B minireceptor cells Atherosclerosis High 21420681
2012 LRP1B expression is required for C1q-mediated neuroprotection against fibrillar and oligomeric amyloid-β toxicity; silencing LRP1B expression inhibits C1q-mediated neuroprotection in primary neurons; LRP1B expression is induced in hippocampus of 3×Tg AD mice early (2 months) in a C1q-dependent manner. siRNA silencing of LRP1B in primary neurons; neurotoxicity assays with fAβ and oAβ; gene expression analysis; in vivo hippocampal expression in transgenic AD mice with and without C1q deficiency The Journal of biological chemistry Medium 23150673
2012 LRP1B mediates cellular uptake of liposomal doxorubicin but not free doxorubicin; reducing LRP1B expression decreased sensitivity of ovarian cancer cell lines to liposomal doxorubicin, while LRP1B overexpression increased sensitivity, functionally demonstrating LRP1B as an endocytic receptor for liposomes. Functional studies: LRP1B knockdown and overexpression in high-grade serous ovarian cancer cell lines; cytotoxicity assays with liposomal doxorubicin vs. free doxorubicin Cancer research Medium 22896685
2013 Knockdown of LRP1B in HEK293 and renal cancer cells promotes anchorage-independent growth, cell migration, and invasion; silencing LRP1B alters expression of focal adhesion complex-associated proteins and increases Cdc42/RhoA activity, implicating LRP1B as a regulator of cytoskeletal dynamics via the RhoA/Cdc42 pathway. shRNA knockdown; anchorage-independent growth assay; migration and invasion assays; Western blot for focal adhesion proteins; Cdc42/RhoA activity assays Cancer science Medium 23521319
2016 Expression of full-length LRP1B (~600 kDa, single polypeptide) in non-small cell lung cancer cells with low endogenous LRP1B significantly reduced cellular proliferation, while siRNA-mediated knockdown in cells with higher endogenous LRP1B enhanced proliferation, confirming a growth-suppressing function. Full-length murine Lrp1b cDNA transfection in NSCLC cell lines; Western blot (600 kDa band); siRNA knockdown; proliferation assays Oncotarget Medium 27626682
2017 LRP1B interacts with DVL2 (Dishevelled 2) and inhibits the DVL2–Axin interaction, thereby negatively regulating β-catenin/TCF Wnt signaling; LRP1B overexpression suppressed growth, migration, and metastasis of colon cancer cells. Co-immunoprecipitation (LRP1B-DVL2 interaction); competitive co-IP (DVL2-Axin); TCF reporter assay; growth, migration, and metastasis assays with LRP1B overexpression/knockdown Experimental cell research Medium 28408316
2020 HSF1 directly regulates transcription of LRP1B; LRP1B knockdown in HCC cells decreases intracellular lipid content, downregulates lipid synthesis enzymes, upregulates β-oxidation enzymes, and activates AMPK signaling, demonstrating LRP1B's role in hepatic lipid metabolism. CRISPR-Cas9 knockdown and CRISPRa activation of LRP1B; Oil Red O staining; DiD staining + flow cytometry; transmission electron microscopy; qPCR and Western blot for metabolic enzymes; AMPK pathway analysis Journal of hepatocellular carcinoma Medium 33324588
2022 LRP1B directly binds NCSTN (nicastrin) and affects its protein expression level, thereby regulating the PI3K/AKT signaling pathway; LRP1B knockdown promotes HCC cell proliferation and migration and enhances resistance to liposomal doxorubicin. Co-immunoprecipitation (LRP1B-NCSTN); Western blot for PI3K/AKT pathway components; in vitro and in vivo proliferation, migration, and drug resistance assays Genes & diseases Medium 37492741
2022 LRP1B deletion in HPV+ oropharyngeal squamous cell carcinoma cell lines (by CRISPR/Cas9) results in increased proliferation, clonogenic growth, migration, and resistance to both cisplatin and radiation in vitro and in vivo (xenograft model). siRNA knockdown; CRISPR/Cas9 deletion in four HPV+ cell lines; proliferation assays; clonogenic assay; migration assay; cisplatin and radiation resistance assays; cell line derived xenograft studies Oral oncology Medium 37778229
2022 LRP1B knockdown activates the PERK-ATF4-CHOP endoplasmic reticulum stress signaling pathway in HCC cells, thereby inhibiting HCC cell proliferation, migration, and invasion and increasing sensitivity to doxorubicin. siRNA/shRNA knockdown of LRP1B; Western blot and qPCR for PERK-ATF4-CHOP pathway components; proliferation, migration, invasion assays; doxorubicin sensitivity assay Bioengineered Low 35389768
2023 LRP1B knockdown in lung adenocarcinoma cells enhances secretion of IL-6 and IL-8 and activates the IL-6-JAK-STAT3 signaling pathway, as confirmed by ELISA, PCR, and Western blot, placing LRP1B as a suppressor of inflammation-driven malignant progression in LUAD. shRNA knockdown of LRP1B; ELISA for IL-6 and IL-8; qPCR and Western blot for JAK-STAT3 pathway components; transcriptomic enrichment analysis American journal of cancer research Low 37560001
2023 Dual sgRNA CRISPR/Cas9 disruption of LRP1B in U87 glioblastoma cells results in altered cellular morphology, increased cellular and nuclear size, changes in ploidy, decreased cell growth in vitro and in vivo (CAM assay), and changes in the secretome profile. Dual sgRNA CRISPR/Cas9 editing; PCR and Sanger sequencing confirmation; qRT-PCR; proteomic secretome analysis; in vitro growth assays; in vivo CAM assay International journal of molecular sciences Medium 37511044
2024 LRP1B regulates sensitivity of NSCLC cells to ferroptosis by modulating SLC7A11 expression through altering STAT3 phosphorylation; LRP1B knockdown promotes ferroptosis sensitivity and enhances anti-PD-1 immunotherapy efficacy in vivo. qRT-PCR, Western blotting, CCK-8 assay, flow cytometry for ferroptosis; ChIP assay; dual-luciferase reporter assay; in vivo mPD-1 immunotherapy experiment Cancer medicine Medium 39660409
2025 DNMT3B directly binds the LRP1B promoter and mediates its hypermethylation, suppressing LRP1B expression in pheochromocytoma; DNMT3B inhibition derepresses LRP1B and inhibits tumor progression; overexpression of DNMT3B reverses the inhibitory effect of LRP1B overexpression. ChIP (DNMT3B binding to LRP1B promoter); luciferase reporter assay; shRNA knockdown; clonal formation, migration assays; in vivo transplantation; RT-qPCR, Western blot, IHC Epigenetics & chromatin Medium 40346661
2004 Restoration of LRP1B expression in esophageal squamous cell carcinoma (ESC) cells reduced colony formation, providing functional evidence that LRP1B suppresses tumor cell growth; LRP1B silencing in ESC lines without homozygous deletion correlates with CpG island hypermethylation, and 5-aza-2'-deoxycytidine treatment restores LRP1B expression; histone acetylation status correlates directly with LRP1B expression. Array CGH; bisulfite-PCR and sequencing; 5-aza-2'-deoxycytidine treatment; colony formation assay after LRP1B restoration; histone acetylation analysis Cancer research Medium 15172977

Source papers

Stage 0 corpus · 67 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2019 Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades. Frontiers in immunology 152 31164891
2012 C1q-induced LRP1B and GPR6 proteins expressed early in Alzheimer disease mouse models, are essential for the C1q-mediated protection against amyloid-β neurotoxicity. The Journal of biological chemistry 129 23150673
2004 Frequent silencing of low density lipoprotein receptor-related protein 1B (LRP1B) expression by genetic and epigenetic mechanisms in esophageal squamous cell carcinoma. Cancer research 128 15172977
2001 The putative tumor suppressor LRP1B, a novel member of the low density lipoprotein (LDL) receptor family, exhibits both overlapping and distinct properties with the LDL receptor-related protein. The Journal of biological chemistry 121 11384978
2021 LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types. Journal for immunotherapy of cancer 98 33653800
2000 LRP-DIT, a putative endocytic receptor gene, is frequently inactivated in non-small cell lung cancer cell lines. Cancer research 98 10766186
2012 LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin. Cancer research 86 22896685
2013 Down expression of LRP1B promotes cell migration via RhoA/Cdc42 pathway and actin cytoskeleton remodeling in renal cell cancer. Cancer science 73 23521319
2010 Chromosomal, epigenetic and microRNA-mediated inactivation of LRP1B, a modulator of the extracellular environment of thyroid cancer cells. Oncogene 72 21057533
2002 Alteration of the LRP1B gene region is associated with high grade of urothelial cancer. Laboratory investigation; a journal of technical methods and pathology 72 12004004
2000 Genomic organization of a new candidate tumor suppressor gene, LRP1B. Genomics 67 11031110
2017 Down-regulation of LRP1B in colon cancer promoted the growth and migration of cancer cells. Experimental cell research 66 28408316
2021 LRP1B: A Giant Lost in Cancer Translation. Pharmaceuticals (Basel, Switzerland) 57 34577535
2004 Normal development and fertility of knockout mice lacking the tumor suppressor gene LRP1b suggest functional compensation by LRP1. Molecular and cellular biology 57 15082773
2022 LRP1B suppresses HCC progression through the NCSTN/PI3K/AKT signaling axis and affects doxorubicin resistance. Genes & diseases 52 37492741
2023 Association between the LRP1B and APOE loci and the development of Parkinson's disease dementia. Brain : a journal of neurology 43 36348503
2015 LRP1B deletion is associated with poor outcome for glioblastoma patients. Journal of the neurological sciences 43 26428308
2016 Expression of a recombinant full-length LRP1B receptor in human non-small cell lung cancer cells confirms the postulated growth-suppressing function of this large LDL receptor family member. Oncotarget 41 27626682
2021 LRP1B or TP53 mutations are associated with higher tumor mutational burden and worse survival in hepatocellular carcinoma. Journal of Cancer 40 33391418
2011 LRP1b shows restricted expression in human tissues and binds to several extracellular ligands, including fibrinogen and apoE-carrying lipoproteins. Atherosclerosis 38 21420681
2010 Ectodomains of the LDL receptor-related proteins LRP1b and LRP4 have anchorage independent functions in vivo. PloS one 34 20383322
2019 Hypoxia induced microRNA-301b-3p overexpression promotes proliferation, migration and invasion of prostate cancer cells by targeting LRP1B. Experimental and molecular pathology 33 31442444
2004 LRP1B attenuates the migration of smooth muscle cells by reducing membrane localization of urokinase and PDGF receptors. Arteriosclerosis, thrombosis, and vascular biology 33 15166012
2017 Integrative analysis of genomic sequencing data reveals higher prevalence of LRP1B mutations in lung adenocarcinoma patients with COPD. Scientific reports 28 28522810
2022 Co-Mutation of FAT3 and LRP1B in Lung Adenocarcinoma Defines a Unique Subset Correlated With the Efficacy of Immunotherapy. Frontiers in immunology 27 35069585
2015 LRP1B, BRD2 and CACNA1D: new candidate genes in fetal metabolic programming of newborns exposed to maternal hyperglycemia. Epigenomics 25 26586120
2021 LRP1B mutation is associated with tumor HPV status and promotes poor disease outcomes with a higher mutation count in HPV-related cervical carcinoma and head & neck squamous cell carcinoma. International journal of biological sciences 24 33994859
2015 Genome-wide haplotype association study identify TNFRSF1A, CASP7, LRP1B, CDH1 and TG genes associated with Alzheimer's disease in Caribbean Hispanic individuals. Oncotarget 24 26621834
2010 A genome screen of successful aging without cognitive decline identifies LRP1B by haplotype analysis. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics 23 19367585
2020 Effects of LRP1B Regulated by HSF1 on Lipid Metabolism in Hepatocellular Carcinoma. Journal of hepatocellular carcinoma 22 33324588
2022 TP53 and LRP1B Co-Wild Predicts Improved Survival for Patients with LUSC Receiving Anti-PD-L1 Immunotherapy. Cancers 17 35884443
2021 Correlation between LRP1B Mutations and Tumor Mutation Burden in Gastric Cancer. Computational and mathematical methods in medicine 17 34603481
2023 The tumor biological significance of RNF43 and LRP1B in gastric cancer is complex and context-dependent. Scientific reports 15 36823311
2019 miR-500 promotes cell proliferation by directly targetting LRP1B in prostate cancer. Bioscience reports 15 30877185
2019 Corrigendum: Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades. Frontiers in immunology 14 31312207
2023 Suppression of tumorigenesis in LUAD by LRP1B through regulation of the IL-6-JAK-STAT3 pathway. American journal of cancer research 13 37560001
2019 The genetic and epigenetic association of LDL Receptor Related Protein 1B (LRP1B) gene with childhood obesity. Scientific reports 13 30755693
2023 Loss of LRP1B expression drives acquired chemo and radio-resistance in HPV-positive head and neck cancer. Oral oncology 12 37778229
2022 Downregulation of Low-density lipoprotein receptor-related protein 1B (LRP1B) inhibits the progression of hepatocellular carcinoma cells by activating the endoplasmic reticulum stress signaling pathway. Bioengineered 12 35389768
2022 Circ-LRP1B functions as a competing endogenous RNA to regulate proliferation, apoptosis and oxidative stress of LPS-induced human C28/I2 chondrocytes. Journal of bioenergetics and biomembranes 10 35274224
2022 Potential predictive value of comutant LRP1B and FAT for immune response in non-small cell lung cancer: LRP1B and FAT comutation enhance immune response. Translational oncology 10 35905642
2014 Coronary artery aneurysms occurrence risk analysis between Kawasaki disease and LRP1B gene in Taiwanese children. BioMedicine 10 25520923
2005 LRP1B is a negative modulator of increased migration activity of intimal smooth muscle cells from rabbit aortic plaques. Biochemical and biophysical research communications 10 15882972
2023 Using a Dual CRISPR/Cas9 Approach to Gain Insight into the Role of LRP1B in Glioblastoma. International journal of molecular sciences 9 37511044
2021 LRP1B Expression as a Putative Predictor of Response to Pegylated Liposomal Doxorubicin Treatment in Ovarian Cancer. Pathobiology : journal of immunopathology, molecular and cellular biology 9 34689147
2019 Cytological Immunostaining of HMGA2, LRP1B, and TP63 as Potential Biomarkers for Triaging Human Papillomavirus-Positive Women. Translational oncology 9 31102921
2019 LRP1B Polymorphisms Are Associated with Multiple Myeloma Risk in a Chinese Han Population. Journal of Cancer 8 30719154
2024 Antithetical impacts of deleterious LRP1B mutations in non-squamous and squamous NSCLCs on predicting benefits from immune checkpoint inhibitor alone or with chemotherapy over chemotherapy alone: retrospective analyses of the POPLAR/OAK and CHOICE-01 trials. Science China. Life sciences 7 39276256
2024 LRP1B Suppresses Immunotherapy Efficacy in Lung Adenocarcinoma by Preventing Ferroptosis. Cancer medicine 6 39660409
2008 Identification of LRP1B-interacting proteins and inhibition of protein kinase Calpha-phosphorylation of LRP1B by association with PICK1. FEBS letters 6 19071120
2025 Comprehensive genetic variant analysis reveals combination of KRAS and LRP1B as a predictive biomarker of response to immunotherapy in patients with non-small cell lung cancer. Journal of experimental & clinical cancer research : CR 5 40011914
2022 Multi-omics data identified TP53 and LRP1B as key regulatory gene related to immune phenotypes via EPCAM in HCC. Cancer medicine 5 35150083
2020 Case Report of acute myeloid leukemia with "WT1, ATRX, CEBPA, CSMD1, IKZF1, and LRP1B mutation and translocation between chromosome 1 and 19" developing from Philadelphia-negative chronic myeloid leukemia after TKI therapy. Medicine 5 32011516
2020 Translational study of the whole transcriptome in rats and genetic polymorphisms in humans identifies LRP1B and VPS13A as key genes involved in tolerance to cocaine-induced motor disturbances. Translational psychiatry 5 33159041
2024 LRP1B mutation is associated with lymph node metastasis in endometrial carcinoma: A clinical next-generation sequencing study. The International journal of biological markers 4 39686583
2023 Integrative analysis of the proteome and transcriptome in gastric cancer identified LRP1B as a potential biomarker. Biomarkers in medicine 4 36606427
2024 LRP1B associated with immune cell infiltration influenced the efficacy of immunotherapy in colorectal cancer patients. Clinics (Sao Paulo, Brazil) 3 39532036
2023 MN1 altered astroblastoma with APC and LRP1B gene mutations: a unique variant in the cervical spine of a pediatric patient. Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 3 36648513
2023 MicroRNA-196a-5p targeting LRP1B modulates phenotype of thyroid carcinoma cells. Endokrynologia Polska 3 36916542
2025 Molecular characteristics and cancer immunity of LRP1B and its relationship with the Hedgehog signaling pathway in colorectal cancer. Frontiers in immunology 2 40170839
2025 LRP1b Loss Predicts Sensitivity to Immunotherapy in Patients with NSCLC: An Analysis of the Phase III CheckMate-026 Randomized Trial. Clinical cancer research : an official journal of the American Association for Cancer Research 2 41065506
2022 Profound tumor response to combined CTLA-4 and PD-1 inhibition in systemic fourth line therapy observed in a patient with hepatocellular carcinoma harboring SETD2 and LRP1B mutations. Zeitschrift fur Gastroenterologie 2 36379463
2025 DNMT3B promotes the progression of pheochromocytoma by mediating the hypermethylation of LRP1B promoter. Epigenetics & chromatin 0 40346661
2025 LRP1B in cancer: From a mutation landscape to predictive biomarkers for precision oncology. Mutation research. Reviews in mutation research 0 41218518
2024 Myoepithelial-Rich Pleomorphic Adenoma With Novel PLAG1 Inversion on Chromosome 8, and LRP1B, PBRM1 and TCF3 Mutations. Cytopathology : official journal of the British Society for Clinical Cytology 0 39549024
2023 Retracted: Correlation between LRP1B Mutations and Tumor Mutation Burden in Gastric Cancer. Computational and mathematical methods in medicine 0 37811213
2009 [Silencing LRP1B with huge transcript by RNAi method]. Yi chuan = Hereditas 0 19138899

Missed literature

Know a paper Affinage missed for LRP1B? Flag it for the maintainers and the community.

No submissions yet.